1
|
López-Canoa JN, Couselo-Seijas M, Baluja A, González-Melchor L, Rozados A, Llorente-Cortés V, de Gonzalo-Calvo D, Guerra JM, Vilades D, Leta R, Martínez-Sande JL, García-Seara FJ, Fernández-López XA, González-Juanatey JR, Eiras S, Rodríguez-Mañero M. Sex-related differences of fatty acid-binding protein 4 and leptin levels in atrial fibrillation. Europace 2021; 23:682-690. [PMID: 33319222 DOI: 10.1093/europace/euaa284] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 05/23/2020] [Accepted: 09/07/2020] [Indexed: 12/26/2022] Open
Abstract
AIMS Adiposity plays a key role in the pathogenesis of atrial fibrillation (AF). Our aim was to study the sex differences in adipokines levels according to AF burden. METHODS AND RESULTS Two independent cohorts of patients were studied: (i) consecutive patients with AF undergoing catheter ablation (n = 217) and (ii) a control group (n = 105). (i) Adipokines, oxidative stress, indirect autonomic markers, and leucocytes mRNA levels were analysed; (ii) correlation between biomarkers was explored with heatmaps and Kendall correlation coefficients; and (iii) logistic regression and random forest model were used to determine predictors of AF recurrence after ablation. Our results showed that: (i) fatty acid-binding protein 4 (FABP4) and leptin levels were higher in women than in men in both cohorts (P < 0.01). In women, FABP4 levels were higher on AF cohort (20 ± 14 control, 29 ± 18 paroxysmal AF and 31 ± 17 ng/mL persistent AF; P < 0.01). In men, leptin levels were lower on AF cohort (22 ± 15 control, 13 ± 16 paroxysmal AF and 13 ± 11 ng/mL persistent AF; P < 0.01). (ii) In female with paroxysmal AF, there was a lower acetylcholinesterase and higher carbonic anhydrase levels with respect to men (P < 0.05). (iii) Adipokines have an important role on discriminate AF recurrence after ablation. In persistent AF, FABP4 was the best predictor of recurrence after ablation (1.067, 95% confidence interval 1-1.14; P = 0.046). CONCLUSION The major finding of the present study is the sex-based differences of FABP4 and leptin levels according to AF burden. These adipokines are associated with oxidative stress, inflammatory and autonomic indirect markers, indicating that they may play a role in AF perpetuation.
Collapse
Affiliation(s)
- J N López-Canoa
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain
| | - M Couselo-Seijas
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain
| | - A Baluja
- Critical Patient Translational Research Group, Department of Anesthesiology, Intensive Care and Pain Management, University Clinical Hospital of Santiago de Compostela, Spain
| | - L González-Melchor
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain
| | - A Rozados
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain
| | - V Llorente-Cortés
- Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Spain.,Biomedical Research Institute Sant Pau (IIB Sant Pau), Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - D de Gonzalo-Calvo
- Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Spain.,Biomedical Research Institute Sant Pau (IIB Sant Pau), Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - J M Guerra
- CIBERCV, Institute of Health Carlos III, Madrid, Spain.,Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica-Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M a Claret, Spain
| | - D Vilades
- Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica-Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M a Claret, Spain
| | - R Leta
- Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica-Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M a Claret, Spain
| | - J L Martínez-Sande
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - F J García-Seara
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - X A Fernández-López
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain
| | - J R González-Juanatey
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - S Eiras
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - M Rodríguez-Mañero
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
2
|
Lopez-Canoa J, Couselo-Seijas M, Baluja A, Gonzalez-Melchor L, Rozados A, Llorente-Cortes V, De Gonzalo-Calvo D, Guerra J, Vilades D, Leta R, Martinez-Sande J, Garcia-Seara F, Gonzalez-Juanatey J, Eiras S, Rodriguez-Manero M. Gender-dependent regulation of FABP4 and leptin according to atrial fibrillation burden. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aims
Adiposity plays a key role in the pathogenesis of atrial fibrillation (AF). Its associated proteins are differentially released between male and female. FABP4 and leptin are mediators in adipose tissue-inflammatory effects. Our aim was to study their gender differential behavior on mechanisms associated with AF progression.
Methods and results
Two independent cohorts were analyzed: A) patients referred for AF catheter ablation (n=217) and patients with suspected coronary artery disease referred for a CT scan (without previous history of AF) (n=105). Protein levels were determined by multiplex fluorometric immunoassay. Gene mRNA expression was analyzed by real time polymerase chain reaction. Correlation between biomarkers was explored with heatmaps and Kendall correlation coefficients. Logistic regression and random forest model determined the best predictors of AF recurrence after catheter ablation. Our results showed: 1) a distinctive profile according to gender, with an increment of FABP4 levels in women (20±14, 29±18 and 31±17 ng/mL; p=0.007) and a decrease of leptin levels in men (22±15, 13±16 and 13±11 ng/mL; p=0.001) among control, paroxysmal and persistent AF groups, respectively; 2) sex differences regarding inflammatory profile, oxidative stress and autonomic indirect markers in AF; 3) a prominent role of adipokines to discriminate AF recurrence after ablation. In persistent AF, FABP4 was the best predictor (LR coefficient 1.067, 95% CI 1–1.14, p=0.046).
Conclusion
The major finding of the present study is the sex differences of FABP4 and leptin according to AF burden. The relationship of these adipokines with oxidative stress, inflammatory and autonomic indirect markers might explain part of the mechanisms underlying the AF perpetuation.
Adipokines regarding Gender & AF burden
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Institute of Health Carlos III
Collapse
Affiliation(s)
- J.N Lopez-Canoa
- University Hospital of Santiago de Compostela, Cardiology group. Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain
| | | | - A Baluja
- University Hospital of Santiago de Compostela, Anesthesiology and Critical Care. Critical Patient Traslational Research Group, Santiago de Compostela, Spain
| | - L Gonzalez-Melchor
- University Hospital of Santiago de Compostela, Cardiology group. Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain
| | - A Rozados
- Health Research Institute, Santiago de Compostela, Spain
| | - V Llorente-Cortes
- Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, CIBERCV, Barcelona, Spain
| | - D De Gonzalo-Calvo
- Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, CIBERCV, Barcelona, Spain
| | - J.M Guerra
- Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, CIBERCV, Barcelona, Spain
| | - D Vilades
- University Hospital of Santa Creu i Sant Pau, Cardiology group, Barcelona, Spain
| | - R Leta
- University Hospital of Santa Creu i Sant Pau, Cardiology group, Barcelona, Spain
| | - J.L Martinez-Sande
- University Hospital of Santiago de Compostela, Cardiovascular area and Coronary Unit. Health Research Institute of Santiago de Compostela. CIBERCV., Santiago de Compostela, Spain
| | - F.J Garcia-Seara
- University Hospital of Santiago de Compostela, Cardiovascular area and Coronary Unit. Health Research Institute of Santiago de Compostela. CIBERCV., Santiago de Compostela, Spain
| | - J.R Gonzalez-Juanatey
- University Hospital of Santiago de Compostela, Cardiovascular area and Coronary Unit. Health Research Institute of Santiago de Compostela. CIBERCV., Santiago de Compostela, Spain
| | - S Eiras
- Health Research Institute, CIBERCV, Santiago de Compostela, Spain
| | - M Rodriguez-Manero
- University Hospital of Santiago de Compostela, Cardiovascular area and Coronary Unit. Health Research Institute of Santiago de Compostela. CIBERCV., Santiago de Compostela, Spain
| |
Collapse
|